Sizes of these terms reflect their relevance to your search.
A recent paper published in Nature Medicine by Calle et al. reported anti-nonalcoholic steatohepatitis (NASH) efficiencies by acetyl-CoA carboxylase (ACC) 1/2 inhibitors alone or by co-administration with a ACC1/2 inhibitor and a diacylglycerol acyltransferase 2 (DGAT2) inhibitor. Whereas the monotherapy achieved remarkable reductions in liver steatosis but induced hyperlipidemia, DGAT2 inhibitor co-administration mitigated the increase in serum triglycerides (TGs). Copyright © 2021 Elsevier Ltd. All rights reserved.
Citation
Xiao-Jing Zhang, Jingjing Cai, Hongliang Li. Targeting ACC for NASH resolution. Trends in molecular medicine. 2022 Jan;28(1):5-7
Mesh Tags
Substances
PMID: 34844875
View Full Text
